Sequana Medical N.V. Stock price




Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 11:35:25 2023-12-08 am EST Intraday chart for Sequana Medical N.V. 5-day change 1st Jan Change
3.15 EUR +4.65% +14.55% -47.50%
Sales 2023 * 891K 959K Sales 2024 * 27.84M 29.97M Capitalization 88.96M 95.76M
Net income 2023 * -33M -35.52M Net income 2024 * -4M -4.31M EV / Sales 2023 *
Net Debt 2023 * 14.15M 15.23M Net Debt 2024 * 24.3M 26.15M EV / Sales 2024 *
P/E ratio 2023 *
P/E ratio 2024 *
Employees 70
Yield 2023 *
Yield 2024 *
Free-Float 87.39%
More Fundamentals * Assessed data
Dynamic Chart
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure CI
Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director CI
Certain Shares of Sequana Medical NV are subject to a Lock-Up Agreement Ending on 22-OCT-2023. CI
Transcript : Sequana Medical NV - Special Call CI
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome CI
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Sequana Medical NV, H1 2023 Earnings Call, Sep 14, 2023 CI
Belgium’s Sequana Medical Enrolls First Patient in Early-stage Trial for Treatment of Chronic Heart Failure MT
Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure CI
Sequana Medical NV Announces Completion of 1,000th Alfapump Implant CI
Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director CI
Transcript : Sequana Medical NV - Special Call CI
Sequana Medical Secures US FDA Clearance for Investigational New Drug Application MT
Belgium's Sequana Medical Raises EUR16 Million to Advance Clinical Programs MT
Sequana Medical NV announced a financing transaction CI
More news
1 day+4.65%
1 week+14.55%
Current month+18.87%
1 month+12.50%
3 months-3.96%
6 months-1.87%
Current year-47.50%
More quotes
1 week
Extreme 2.76
1 month
Extreme 2.32
Current year
Extreme 2.22
1 year
Extreme 2.22
3 years
Extreme 2.22
5 years
Extreme 2.22
10 years
Extreme 2.22
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 2015
Director of Finance/CFO 49 -
Chief Tech/Sci/R&D Officer 59 2020
Members of the board TitleAgeSince
Director/Board Member 65 2022
Director/Board Member 67 2018
Director/Board Member 62 -
More insiders
Date Price Change Volume
23-12-08 3.15 +4.65% 9,271
23-12-07 3.01 -1.95% 8,381
23-12-06 3.07 +9.64% 17,570
23-12-05 2.8 0.00% 14,722
23-12-04 2.8 +1.82% 7,751

Real-time Euronext Bruxelles, December 08, 2023 at 11:35 am EST

More quotes
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Sequana Medical N.V. - Euronext Bruxelles
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments